No headlines found.
GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility Output
Globe Newswire (Mon, 14-Sep 8:30 AM ET)
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Globe Newswire (Fri, 4-Sep 5:00 PM ET)
Business Wire (Thu, 30-Jul 8:00 AM ET)
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
Matinas Biopharma Hldgs trades on the AMEX stock market under the symbol MTNB.
As of October 14, 2026, MTNB stock price declined to $2.48 with 19,301 million shares trading.
MTNB has a beta of 1.02, meaning it tends to be more sensitive to market movements. MTNB has a correlation of 0.00 to the broad based SPY ETF.
MTNB has a market cap of $36.44 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, MTNB traded as high as $4.49 and as low as $.09.
The top ETF exchange traded funds that MTNB belongs to (by Net Assets): VXF.
MTNB has outperformed the market in the last year with a return of +30.5%, while the SPY ETF gained +17.4%. In the last 3 month period, MTNB beat the market returning +609.0%, while SPY returned +2.6%. However, in the most recent 2 weeks MTNB has underperformed the stock market by returning -2.7%, while SPY returned +0.9%.
MTNB support price is $2.29 and resistance is $2.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MTNB shares will trade within this expected range on the day.
